NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Ascending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
48818-0001-02 | 48818-0001 | Pralatrexate | Folotyn | 20.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 24, 2009 | Feb. 29, 2024 | No Longer Used |
50268-0527-15 | 50268-0527 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 26, 2021 | In Use | |
51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug. 7, 2017 | Jan. 31, 2024 | No Longer Used |
59923-0721-60 | 59923-0721 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2020 | In Use | |
59923-0722-12 | 59923-0722 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2020 | In Use | |
64980-0276-06 | 64980-0276 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 1, 2017 | In Use | |
64980-0277-12 | 64980-0277 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 1, 2017 | In Use | |
65162-0843-06 | 65162-0843 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65162-0844-06 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65162-0844-16 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
Found 10,000 results in 8 milliseconds — Export these results